Careone Allergy Relief tablets recalled for failed impurity and degradation specifications
Careone Allergy Relief fexofenadine hydrochloride 180mg tablets are recalled nationwide for failing impurity and degradation specifications. Lot 2JE2185 with expiration date 01/24 is affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving failed pharmaceutical quality specifications (impurities and degradation) constitutes a risk-of-harm product where injury has not yet been reported, meeting the rubric criterion for severity score 3.
Plain-English summary
Careone Allergy Relief fexofenadine hydrochloride 180mg tablets are being recalled due to failed impurity and degradation testing specifications. The affected product is a 15-count carton distributed by Adusa Distribution, LLC in Salisbury, North Carolina.
The manufacturer, L. Perrigo Company, initiated this recall after determining that certain lots failed to meet established specifications for impurities and product degradation. This is classified as a Class II recall by the FDA.
The recall affects 3,240 cartons distributed nationwide within the United States. Lot 2JE2185 with expiration date 01/24 is specifically identified as part of this recall.
The recalled product
- Product
- CAREONE ALLERGY RELIEF (FEXOFENADINE HYDROCHLORIDE)
- Brand
- CAREONE ALLERGY RELIEF
- Manufacturer
- L. Perrigo Company
- Category
- Drug
- Hazard
- impurity
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 2JE2185
- Exp. date 01/24
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CAREONE ALLERGY RELIEF
- ModerateCAREONE Allergy Relief 180 mg Tablets Recalled for Failed Impurities Specifications
FDA (Drugs) · 2022-01-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27